Agomelatine hydrochlorideCAS# 1176316-99-6 |
- AM580
Catalog No.:BCC5373
CAS No.:102121-60-8
- AGN 194310
Catalog No.:BCC5416
CAS No.:229961-45-9
- Palovarotene
Catalog No.:BCC4185
CAS No.:410528-02-8
- AGN 205728
Catalog No.:BCC5418
CAS No.:859498-05-8
- AGN 196996
Catalog No.:BCC5417
CAS No.:958295-17-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1176316-99-6 | SDF | Download SDF |
| PubChem ID | 66980040 | Appearance | Powder |
| Formula | C15H18ClNO2 | M.Wt | 279.76 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (357.45 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide;hydrochloride | ||
| SMILES | CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC.Cl | ||
| Standard InChIKey | ZJVMEXOLMFNQPX-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C15H17NO2.ClH/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13;/h3-7,10H,8-9H2,1-2H3,(H,16,17);1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Agomelatine hydrochloride Dilution Calculator
Agomelatine hydrochloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.5745 mL | 17.8725 mL | 35.7449 mL | 71.4898 mL | 89.3623 mL |
| 5 mM | 0.7149 mL | 3.5745 mL | 7.149 mL | 14.298 mL | 17.8725 mL |
| 10 mM | 0.3574 mL | 1.7872 mL | 3.5745 mL | 7.149 mL | 8.9362 mL |
| 50 mM | 0.0715 mL | 0.3574 mL | 0.7149 mL | 1.4298 mL | 1.7872 mL |
| 100 mM | 0.0357 mL | 0.1787 mL | 0.3574 mL | 0.7149 mL | 0.8936 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Agomelatine is a competitive antagonist of human and porcine serotonin (5-HT2C) receptors (pKi = 6.2 and 6.4, respectively) as well as human 5-HT2B receptors (pKi = 6.6).
- 3-Cyano-7-ethoxycoumarin
Catalog No.:BCC7979
CAS No.:117620-77-6
- 16-Oxocleroda-3,13E-dien-15-oic acid
Catalog No.:BCN7286
CAS No.:117620-72-1
- 1-Hydroxy-1-(4-hydroxy-2-methoxyphenyl)-3-(4-hydroxyphenyl)propan-2-one
Catalog No.:BCN1607
CAS No.:117614-84-3
- 6-Hydroxymethylherniarin
Catalog No.:BCN3573
CAS No.:117597-79-2
- Coronarin E
Catalog No.:BCN6052
CAS No.:117591-81-8
- Calpeptin
Catalog No.:BCC2351
CAS No.:117591-20-5
- DMXAA (Vadimezan)
Catalog No.:BCC3644
CAS No.:117570-53-3
- threo-6'-Hydroxyustusolate C
Catalog No.:BCN6930
CAS No.:1175543-07-3
- Ustusolate E
Catalog No.:BCN7789
CAS No.:1175543-06-2
- 2alpha,9alpha,11-Trihydroxy-6-oxodrim-7-ene
Catalog No.:BCN7741
CAS No.:1175543-03-9
- Ustusol A
Catalog No.:BCN7719
CAS No.:1175543-02-8
- Neuromedin U (rat)
Catalog No.:BCC5847
CAS No.:117505-80-3
- LY 255283
Catalog No.:BCC7290
CAS No.:117690-79-6
- DL-Syringaresinol
Catalog No.:BCN6053
CAS No.:1177-14-6
- Laxogenin
Catalog No.:BCN8434
CAS No.:1177-71-5
- Dexamethasone acetate
Catalog No.:BCC4775
CAS No.:1177-87-3
- Doramectin
Catalog No.:BCC1536
CAS No.:117704-25-3
- CKI 7 dihydrochloride
Catalog No.:BCC5614
CAS No.:1177141-67-1
- (R)-(+)-Blebbistatin
Catalog No.:BCC7195
CAS No.:1177356-70-5
- Felbamate hydrate
Catalog No.:BCC4160
CAS No.:1177501-39-1
- Forsythoside I
Catalog No.:BCN6430
CAS No.:1177581-50-8
- N20C hydrochloride
Catalog No.:BCC7292
CAS No.:1177583-87-7
- SMANT hydrochloride
Catalog No.:BCC6254
CAS No.:1177600-74-6
- CGH 2466 dihydrochloride
Catalog No.:BCC7338
CAS No.:1177618-54-0
Excessive sweating induced by interaction between agomelatine and duloxetine hydrochloride: case report and review of the literature.[Pubmed:25576334]
Wien Klin Wochenschr. 2015 Sep;127(17-18):703-6.
OBJECTIVE: In this case report, we describe a case in which the clinical pharmacy team was asked to provide recommendations on possible continued use of combination antidepressants in a 62-year-old Slovenian female patient with major depressive disorder following agomelatine and duloxetine hydrochloride-induced excessive sweating. When agomelatine was administered as an additional treatment, drug-induced excessive sweating was observed after a daily intake of 90 mg of duloxetine hydrochloride and 25 mg of agomelatine. After thorough discussion, it was decided not to rechallenge with agomelatine because of the serious adverse effect. After agomelatine discontinuation and switching to trazodone, symptoms immediately improved. DISCUSSION: Duloxetine hydrochloride-induced sweating has been reported frequently, but excessive sweating induced by agomelatine and duloxetine hydrochloride has not been reported in the literature. The adverse effect was determined by a clinical pharmacist using the Naranjo probability scale and was probably associated with agomelatine use (6 points) and possibly associated with duloxetine hydrochloride use (4 points). The exact mechanism for this adverse effect in this patient is not known, but we believe that a pharmacodynamic drug-drug interaction between agomelatine and duloxetine hydrochloride had occurred. CONCLUSION: Such a case has not yet been described in literature; however, an adverse effect associated with drug-drug interaction can occur, as this report clearly demonstrates. The benefits of this antidepressant combination need to be carefully balanced with the risks associated with its use. This case report also highlights the increased potential for adverse reactions when prescribing antidepressant combinations and importance of clinical pharmacists' involvement in the psychiatric patients' pharmacotherapy.
